Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Stereotaxis to Present at Upcoming Investor Conferences

April 25, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, April 25, 2011 /- Stereotaxis, Inc. (NASDAQ: STXS ) today announced that executive management will present at the following investor conferences during May 2011: The Deutsche Bank Annual Health Care Conference in Boston.  Michael P. Kaminski, President and Chief Executive...

Two New Studies in the British Medical Journal Find That Bayer's Yaz and Yasmin Birth Control Pills Have an Increased Risk of Blood Clot

April 22, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, April 22, 2011 /PRNewswire-USNewswire/ -- The following release is being issued by law firms RodaNast, P.C.; Levin, Fishbein, Sedran & Berman and Feldman & Pinto: According to two new studies published in the online edition of the British Medical Journal, Bayer's...

PLC Systems' Chief Financial Officer to Leave Company to Become CEO of Clinquest

April 22, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

FRANKLIN, Mass., April 22, 2011 /- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced that its Chief Financial Officer, James G. Thomasch, will leave the company effective May 2, 2011, to become Chief Executive Officer at...


Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Or...

April 22, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

TOKYO, April 22, 2011 /- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and...

ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB®

April 21, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

IRVINGTON, N.Y., April 21, 2011 /- ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMA SORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada. HEMA SORB is a ready-to-use,...

Boston Scientific Announces Results for First Quarter Ended March 31, 2011

April 20, 2011 1:33 pm | by Boston Scientific | News | Comments

NATICK, Mass., April 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2011, as well as net sales and earnings per share (EPS) guidance

ABC News Reports on Aethlon Medical

April 20, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, April 20, 2011 /- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it is the subject of an ABC news story that can be accessed online at:...

Cardiogenesis Corporation to Report 2011 First Quarter Results on May 4th

April 20, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., April 20, 2011 /- Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will release results for its first quarter ended March 31, 2011 on Wednesday, May 4, 2011.  The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott,...


Reportlinker Adds Levosimendan - Comprehensive patent search

April 20, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, April 20, 2011 /- announces that a new market research report is available in its catalogue: Levosimendan - Comprehensive patent search Eliminate unnecessary risk with the...

Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences

April 19, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

SEATTLE, April 19, 2011 /- Omeros Corporation (NASDAQ: OMER ) today announced that research on mannan-binding lectin-associated serine protease-2 (MASP-2) has been published in the April 18, 2011 Early Online Edition of the Proceedings of the National Academy of Sciences (PNAS)....

Abaxis to Report Fourth Quarter and Fiscal Year 2011 Financial Results Thursday, April 28, 2011

April 19, 2011 5:35 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., April 19, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2011, ended March 31, 2011. The call...

Cumberland Pharmaceuticals Announces New Product Addition With Hepatorenâ„¢ (ifetroban) Injection

April 19, 2011 3:33 am | by Bio-Medicine.Org | News | Comments

NASHVILLE, Tenn., April 19, 2011 /- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II...

CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation

April 18, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

ATLANTA and IRVINE, Calif., April 18, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the expiration of the 20-day "go-shop" period that is part of its definitive agreement with Cardiogenesis...


Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient

April 18, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

GAITHERSBURG, Md., April 18, 2011 /- Sigma-Tau Pharmaceuticals, Inc. is pleased to announce that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture L-asparaginase, the primary ingredient in the oncology medicine ONCASPAR® (pegaspargase)....

$210M Pfizer Deal Validates Small Firm

April 17, 2011 11:33 pm | by San Diego Business Journal | News | Comments

Robin Jackman, Zacharon's president and CEO, is the first to admit that there aren't too many people outside the biotech world who understand the science at the core of his small company.

Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and S...

April 17, 2011 10:34 pm | by Bio-Medicine.Org | News | Comments

MYSTIC, Conn. and DUBLIN, April 18, 2011 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product...

Atrium Provides Grant to Establish Education Web Site at

April 15, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

HUDSON, N.H., April 15, 2011 /- Atrium Medical Corporation has provided an educational grant to establish an educational web site, Atrium University, at .  "Atrium has been proud to be the market leader in educational support for our customers," said Jeff McGill,...

New Test Spots Infections in Hours, Rather than Days

April 14, 2011 8:34 pm | by Massachusetts Institute of Technology | News | Comments

A startup has developed a device that uses magnetic particles to identify pathogens rapidly.

Tips For Enjoying A Healthy And Balanced Life

April 14, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

SHENZHEN, China, April 14, 2011 /PRNewswire-Asia/ In today's modern high-tempo society, people always live a rapid pace of life . Fast food gets more and more popular especially in modern societies in which time is money. People also realize the importance of heath; they pay great...

Varian Medical Systems to Exhibit the Latest Digital Image Detectors, X-Ray Tubes and Cancer Treatment Technologies at the CMEF Show in Shenzhen, China

April 14, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

SALT LAKE CITY, April 14, 2011 /- Booth #H1/E32 -- Varian Medical Systems (NYSE: VAR ) will exhibit a wide selection of X-ray tubes and flat panel image detectors for digital radiography (DR) at the China International Medical Equipment Fair (CMEF) meeting in Shenzhen, China, April 16-18,...

IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®

April 14, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, April 14, 2011 /- The Medical Devices Bureau of Health Canada has granted regulatory approval for the SUPERA VERITAS stent system for use in biliary and peripheral procedures.  IDEV's unique stent was previously available on a limited basis only, through the Special...

NeoStem's Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility

April 13, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

ALLENDALE, N.J., April 13, 2011 /- Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc. (NYSE Amex: NBS ) and an internationally recognized cell therapy services and development company, announced today that it has, once again, demonstrated compliance with the...

According to the Journal of Advanced Nursing, RyMed Technologies' InVision-Plus® Excels at Minimizing Bacterial Growth In Vitro

April 13, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

FRANKLIN, Tenn., April 13, 2011 /- In the Journal of Advanced Nursing March issue, a comparative research evaluation of five needleless I.V. connectors tested by an independent laboratory showed that the RyMed InVision-Plus® (RYM-5001®) zero displacement connector best protected...

Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin

April 12, 2011 11:36 am | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., April 12, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with...

Cluster's Founding Father Leads Firm

April 11, 2011 8:34 am | by San Diego Business Journal | News | Comments

David F. Hale, considered by many to be a founding father of San Diego's mighty biotechnology cluster, has taken the helm at Biocept, a cancer-focused diagnostic and laboratory services company that's getting ready to launch its first product in July.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.